Holista CollTech Ltd (ASX: HCT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Holista CollTech Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$18.09 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
335.05 million
Earnings per share
0.000
Dividend per share
N/A
Year To Date Return
315.38%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Holista CollTech Ltd (ASX: HCT)
Latest News
Healthcare Shares
ASIC accuses ASX company of misleading COVID-19 claims
Speculative
Why the Holista CollTech share price is climbing higher today
Share Market News
ASX stock of the day: This small-cap ASX wellness share jumped 6% today after it filed a global patent
Share Gainers
These ASX shares are fighting the spread of coronavirus
⏸️ Investing
The Holista Colltech share price soars 170% today
HCT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Holista CollTech Ltd
Holista CollTech Ltd is a research-driven biotech company. Its operating segments include Supplements; Ovine Collagen; Infection Control Solutions; Food Ingredients; and Corporate. The supplements segment is involved in the manufacturing and wholesale distribution of dietary supplements. The ovine collagen segment is involved in the manufacturing and distribution of cosmetic grade collagen. The food ingredients segment is involved in the manufacturing and wholesale distribution of healthy food ingredients. The infection control segment is involved in the infection control solutions. The company generates a majority of its revenue from the Supplements segment. Geographically, it generates a majority of its revenue from Malaysia and the rest from Australia and the United States.
HCT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Jun 2025 | $0.05 | $0.00 | 0.00% | 18,674 | $0.06 | $0.06 | $0.05 |
| 19 Jun 2025 | $0.06 | $0.00 | 0.00% | 12,065 | $0.05 | $0.06 | $0.05 |
| 18 Jun 2025 | $0.06 | $-0.01 | -16.13% | 67,243 | $0.06 | $0.06 | $0.05 |
| 17 Jun 2025 | $0.06 | $0.00 | 0.00% | 253,326 | $0.06 | $0.06 | $0.05 |
| 16 Jun 2025 | $0.06 | $0.00 | 0.00% | 154,792 | $0.06 | $0.06 | $0.06 |
| 13 Jun 2025 | $0.06 | $0.00 | 0.00% | 3,542 | $0.06 | $0.06 | $0.06 |
| 12 Jun 2025 | $0.06 | $0.00 | 0.00% | 173,035 | $0.06 | $0.06 | $0.06 |
| 11 Jun 2025 | $0.06 | $0.00 | 0.00% | 201,381 | $0.06 | $0.06 | $0.06 |
| 10 Jun 2025 | $0.06 | $0.00 | 0.00% | 121,347 | $0.06 | $0.06 | $0.05 |
| 06 Jun 2025 | $0.06 | $-0.01 | -15.38% | 150,729 | $0.07 | $0.07 | $0.06 |
| 05 Jun 2025 | $0.07 | $0.00 | 0.00% | 71,016 | $0.06 | $0.07 | $0.06 |
| 04 Jun 2025 | $0.06 | $0.00 | 0.00% | 205,955 | $0.06 | $0.06 | $0.06 |
| 03 Jun 2025 | $0.06 | $0.00 | 0.00% | 163,928 | $0.06 | $0.06 | $0.05 |
| 02 Jun 2025 | $0.06 | $0.00 | 0.00% | 40,064 | $0.06 | $0.06 | $0.06 |
| 30 May 2025 | $0.06 | $0.00 | 0.00% | 83,596 | $0.06 | $0.06 | $0.06 |
| 29 May 2025 | $0.06 | $0.01 | 19.23% | 549,168 | $0.05 | $0.06 | $0.05 |
| 28 May 2025 | $0.05 | $0.00 | 0.00% | 373,416 | $0.05 | $0.05 | $0.05 |
| 27 May 2025 | $0.05 | $0.00 | 0.00% | 27,766 | $0.05 | $0.05 | $0.05 |
| 26 May 2025 | $0.05 | $0.00 | 0.00% | 3,514 | $0.05 | $0.05 | $0.05 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Lai Kwok Kin | Non-Executive Director | Mar 2024 |
Mr Kin is Founder and Managing Director of Singapore-based WeR1 Consultants Pte Ltd which provides counsel for investor relations and crisis communications to companies listed on regional exchanges.
|
| Mr Leong Man Loong | Non-Executive Director | Jan 2025 |
Mr Loong brings expertise in corporate management, financial oversight, and business development. His track record includes driving operational improvements and delivering results in complex environment government. Mr. Leong is an entrepreneur and inventor with 30 years of specialization in: Nanotechnology Green Chemistry, and Environmental Technology. He holds numerous patents and has contributed to advancements in air purification, environmental sustainability, and material recycling across several global industries. Currently, Mr Leong also serves as the Executive Chairman of the Malaysia-headquartered SHEPROS Group of Companies, where he continues to innovate and lead projects that align with the latest in environmental and technological developments. With his executive leadership, the Board believes that Holista is well-positioned to navigate current challenges and work towards a sustainable and profitable future.
|
| Mr Gregory(Greg) Pilant | Non-Executive Director | Mar 2025 |
Mr Pilant, is Founder, CEO and Chairman of CEO of Regenerex Pharma, Inc., which is listed on the OTC in the United States. He brings knowledge of pharmaceutical and biotechnology sectors, especially in the field of regenerative medicine.
|
| Mr Sam Yee Yuen Keong Yee | Non-Executive Director | May 2025 |
Mr Keong has held roles in organisations, in pharmaceuticals, diagnostics, and wellness. His roles at Merck Serono, Beacon International, and Envy Continent (a wellness tourism venture he founded) underscored in business model implementation and strategic articulation. Earlier, at GlaxoSmithKline and Roche, he secured government tenders and elevated brands to market leadership.
|
| Mr Robert Gemelli | Non-Executive Director | May 2025 |
Mr Gemelli began his career in the insurance sector at Federation Insurance, quickly rising to a management position. Transitioning to the entertainment industry, he collaborated with Entertainment Enterprises Pty Ltd, eventually becoming General Manager of the Group. He later established his own entertainment business in Broome, Western Australia, which he sold at a profit.
|
| Mr Jay Richard Stephenson | Company Secretary | Sep 2021 |
-
|
| Jay Richard Stephenson | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Galen Biomedical Inc | 58,514,245 | 20.48% |
| Mr Man Loong Leong | 36,159,845 | 12.65% |
| 818 Corporate Pty Ltd <818 A/C> | 14,072,212 | 4.92% |
| Jaz Future Fund Pty Ltd <Arr Superannuation Fund A/C> | 9,750,000 | 3.41% |
| Ms Sarinderjit Kaur | 9,675,785 | 3.39% |
| Citicorp Nominees Pty Limited | 9,493,983 | 3.32% |
| BNP Paribas Noms Pty Ltd | 9,387,982 | 3.29% |
| Mr Robert Gemelli | 8,715,016 | 3.05% |
| Mr Anthony Robert Ramage | 8,000,000 | 2.80% |
| Perpetual Capital Investments Pty Ltd | 6,966,647 | 2.44% |
| Fairview Holdings Pty Ltd <The Manjule Super A/C> | 6,358,570 | 2.23% |
| BNP Paribas Nominees Pty Ltd <Uob Kh Pl> | 4,792,934 | 1.68% |
| Driscoll Future Pty Ltd <Driscoll Super Fund A/C> | 4,728,498 | 1.65% |
| BNP Paribas Noms Pty Ltd Uobkh A/C R'Miers | 4,142,751 | 1.45% |
| Mr Himmat Singh | 3,500,000 | 1.22% |
| Chandra Sekaran P Perumal | 3,333,333 | 1.17% |
| Ide Super Pty Ltd <Ide Super Fund A/C> | 3,005,221 | 1.05% |
| Perpetual Capital Investments Pty Ltd i | 3,000,000 | 1.05% |
| Chow Siew Moi | 2,935,703 | 1.03% |
| Mr Yeo Soon Keong | 2,600,000 | 0.90% |
